Eli Lilly | LLY - Trade Debtors


Eli Lilly reported $21.18B in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Abbott USD 11.22B 655M Mar/2026
ALKERMES USD 407.63M 73.6M Mar/2026
Amgen USD 9.14B 432M Mar/2026
AstraZeneca USD 17.88B 1.17B Mar/2026
Baxter International USD 1.7B 310M Mar/2026
Biogen USD 1.79B 76.6M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Drreddys Laboratories INR 123.17B 121.76B Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Gilead Sciences USD 4.74B 172M Mar/2026
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Glaxosmithkline GBP 10.49B 40.6M Mar/2026
J&J USD 22.54B 1.21B Mar/2026
Medtronic USD 6.36B 30M Dec/2025
Merck USD 11.78B 345M Dec/2025
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Novo Nordisk DKK 106.26B 11.21B Mar/2026
Perrigo USD 697.1M 84.3M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Phibro Animal Health USD 215.87M 2.02M Dec/2025
Prestige Brands USD 191.92M 1.46M Mar/2026
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Roche Holding CHF 11.9B 460M Dec/2025
Sanofi EUR 482M 85M Mar/2026
Sanofi EUR 482M 85M Mar/2026
United Therapeutics USD 312M 38.2M Mar/2026
Zoetis USD 1.51B 84M Mar/2026